Abstracts tagged "Anti TNF"

Abstract Number: 2472 • 2012 ACR/ARHP Annual Meeting
A Randomized, Multicentre, Double Blind, Placebo-Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory Hand Osteoarthritis: The Dora Study
Xavier Chevalier¹, Philippe Ravaud², Emmanuel Maheu³, Gabriel Baron⁴, Amandine Rialland⁵, Philippe Vergnaud⁶, Christian Roux⁷, Yves Maugars⁸, Denis Mulleman⁹, Bernard Combe¹⁰, Daniel Wendling¹¹, Pierre Laforgue¹², Damien Loeuille¹³, Violaine Foltz¹⁴ and Pascal Richette¹⁵, ¹Department of Rheumatology Hopital Henri Mondor, Créteil, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ⁴Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ⁵Unité de recherche clinique Henri Mondor, Créteil, France, ⁶CCRB Synarc Lyon, Lyon, France, ⁷Rheuamtology, CHU L' Archet University Nice, Nice, France, ⁸Rheumatology, Nantes University Hospital, Nantes, France, ⁹CHU Trousseau Tours, Tours, France, ¹⁰CHU Lapeyronie, Montpellier, France, ¹¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ¹²CHU la conception Marseille, Marseille, France, ¹³Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ¹⁴APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ¹⁵Lariboisière Hospital, Paris, France
Background/Purpose: Hand osteoarthritis (HOA) is a frequent painful polyarticular disease which often does not respond to any classical therapeutics. TNF a is involved in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].